ECM News in Brief, February 17, 2012

17 Feb 2012


Algeta oversubscribed on $75m growth deal

Norwegian cancer drug firm Algeta completed a Nkr429m ($74.9m) two day bookbuild on Wednesday in a capital raise to build up its US sales operation and to fund research and development, while one of its leading shareholders sold a small portion ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.